Rifaximin therapy for patients with irritable bowel syndrome without constipation - Wikidata - wikimedia - TriplyDB

Rifaximin therapy for patients with irritable bowel syndrome without constipation

Rifaximin therapy for patients with irritable bowel syndrome without constipation

http://www.wikidata.org/entity/Q28302405

about

Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk Intestinal microbiota in functional bowel disorders: a Rome foundation report Use of rifaximin in gastrointestinal and liver diseases Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome Gut microbiota role in irritable bowel syndrome: New therapeutic strategies Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation The rise of multiple imputation: a review of the reporting and implementation of the method in medical research Profile of rifaximin and its potential in the treatment of irritable bowel syndrome Abdominal bloating: pathophysiology and treatment Gut microbiota and gastrointestinal health: current concepts and future directions Irritable bowel syndrome: a concise review of current treatment concepts Upper gastrointestinal microbiota and digestive diseases Unraveling the ties between irritable bowel syndrome and intestinal microbiota Measuring response in the gastrointestinal tract in systemic sclerosis Brain-gut axis: from basic understanding to treatment of IBS and related disorders Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications Methanogens, methane and gastrointestinal motility Biomarkers of Irritable Bowel Syndrome Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate Gut bacteria in health and disease Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.Stress and visceral pain: from animal models to clinical therapies Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.It's a gut feeling: how the gut microbiota affects the state of mind.Review article: the treatment of functional abdominal bloating and distension.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway.Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.IBS and the role of otilonium bromide.A combined nutrient and lactulose challenge test allows symptom-based clustering of patients with irritable bowel syndrome.Diagnosis and management of small intestinal bacterial overgrowth.Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial.Effect of a low-flatulogenic diet in patients with flatulence and functional digestive symptoms.Breath tests and irritable bowel syndrome.Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome

P2860

Q24603491-778F7800-9DBE-46C8-BA20-6EDD5B324736 Q24631357-F959B6BD-33E3-404A-B1F1-713660D78F5A Q26740201-F5BD7CDB-92DA-4D02-AB28-2AB61DA70CEA Q26743440-E37117F5-317E-47E4-A291-8CF43595D607 Q26748617-8A1D9491-D57E-455C-84F5-1CB3FAB53D23 Q26765272-7BDC2855-80CB-4EBE-B7BB-E33FAB300977 Q26768550-99EB8D08-369B-497E-8A2E-B4D69D9C8342 Q26772962-F468B9B2-FCA1-44A4-813D-1737A7440019 Q26775927-682F92E7-920E-46F7-A553-7CE77CB2E591 Q26824638-41DB8018-F079-476E-83D0-E2391C7554DB Q26828889-4397896B-B2DA-4BC4-8C72-54F51C6C01C6 Q26829363-BE0C4980-AA9F-4098-8A87-F5CE81EB6F50 Q26851622-76855BED-A728-4E52-B6E5-2746D3D6E3E1 Q26865880-99E90CD4-BAC8-4147-87E1-539DB1723DA2 Q26996547-12B2DC2A-C7F2-462A-B41E-7625E8147518 Q27002380-288C687F-D31E-495B-B186-E81682692415 Q27004645-E16CF541-A852-4DEE-AE48-FE3AA1F72E7D Q27022416-0D47145F-57E6-4D64-86C3-04C8AAE2DBBD Q27024801-7CD2AA59-D2EC-46AC-8CB4-9CAF3C403144 Q27027602-0A876813-B2B5-4733-887F-1EFEE30A418D Q27693339-2FF9CC78-D673-4D05-B27B-5B6279E9978E Q28069902-72D8727E-38A8-4F71-9388-5DC89615E3DD Q28072437-57016B93-5ACD-4944-92AD-5A8138C6200D Q28238138-018437AE-0C5D-4B96-9BB6-E3C22FECADEA Q28239840-0107C601-4E60-4660-B9C0-9334D1B51392 Q30415125-8EA1A202-1070-4536-BD2F-CE4427C70D9E Q30459512-C93396BC-5EAE-4DD1-9E1F-C6AC6B04D311 Q31142368-3E194594-DC69-4628-B72A-B7C8AC6A2C84 Q31154556-780F38B1-9339-46F6-99D5-5C85CB0744A1 Q33450132-B497FB23-FB3A-4C10-A746-676FB28B8BFB Q33451900-AB59E2B4-21CA-46DE-BE25-DA700F4A50B3 Q33456089-05C010E3-B744-4F56-B1D5-E1B25CEAAD62 Q33456102-C8BDF83F-5F9D-4874-AE65-CF10E4410B84 Q33456428-B8D5E201-7DC5-4215-A30F-50203AEB01C2 Q33457676-573E5628-A974-4CF2-B988-64CF1009371B Q33457767-B083A52C-3188-4B6E-AFB6-36ED65CFBC7F Q33459323-602C95D5-A1D5-4C51-919A-1CB80455717E Q33460827-85439211-3406-4F53-97A7-EF24AB8BBDCF Q33462070-7F8C7E99-9D3F-44E6-8A3D-97229CBF80C6 Q33463153-250E6A46-7F4D-4B69-AA56-E92CFFF2C9C6

P2860

Rifaximin therapy for patients with irritable bowel syndrome without constipation

http://www.wikidata.org/entity/Q28302405

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@ast

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@en

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@nl

type

label

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@ast

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@en

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@nl

prefLabel

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@ast

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@en

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@nl

P1433

Q28302405-71ECECCC-751C-4A7D-837D-E17C1296F19B

P1476

Q28302405-9FF04FCE-70F6-4533-854F-9BA79081FAD9

P2093

Q28302405-290C2E0F-3B4C-4EC3-AF4D-FF1978BE2900

Q28302405-4B15CEFA-6CFE-41DC-BA64-6F1385D0124A

Q28302405-51ECFEF8-D73A-462F-882C-53FD6F698041

Q28302405-564ACD2C-C3A1-43C4-BDD5-E20C31BB3F54

Q28302405-A2A41B2E-8623-4FE6-A1BD-A67C82E278FE

Q28302405-AB543D7D-D6B0-4840-967E-42C846065095

Q28302405-C056B7CE-F7AE-45E4-B398-8DC16CB12DCE

Q28302405-C07DB48F-AC2E-4362-A948-1D0FC5C16ED5

Q28302405-EE29152F-39BB-4745-BA4C-7B7E03020F76

P304

Q28302405-9F728F2B-6CEC-4933-9F98-991292830A69

P31

Q28302405-E3588D4E-BCD4-4DDB-B7B2-5ADDC3FCCA3A

P3181

Q28302405-19F5CE57-4127-40A3-8C5F-2D4187913F44

P356

Q28302405-10B03B2A-349E-42EA-BA4C-EDE25CD572A4

P407

Q28302405-9CFEAE20-8C2C-452F-939D-CD738E3F2AC9

P433

Q28302405-D53D2D59-951E-4A9F-8734-BB7D41946838

P478

Q28302405-11E6F504-CA09-4ACB-9B1D-9B2C2A2FDD8A

P50

Q28302405-C81EB993-5A50-4257-8F80-7AD72A47ED4C

P577

Q28302405-29D6EF55-0DFE-4636-BD7E-57905BD124AE

P698

Q28302405-92B02F53-53F9-4670-B1E2-0496EE714EAA

P921

Q28302405-D59231E9-2A28-4E9D-B2F2-0A1FC4BD86DA

P3181

P356

P1433

The New England Journal of Medicine

P1476

Rifaximin therapy for patients with irritable bowel syndrome without constipation

@en

P2093

Anthony Lembo

http://www.w3.org/2001/XMLSchema#string

Audrey L Shaw

http://www.w3.org/2001/XMLSchema#string

Enoch Bortey

http://www.w3.org/2001/XMLSchema#string

Jing Yu

http://www.w3.org/2001/XMLSchema#string

Salam Zakko

http://www.w3.org/2001/XMLSchema#string

Shadreck M Mareya

http://www.w3.org/2001/XMLSchema#string

William D Chey

http://www.w3.org/2001/XMLSchema#string

William P Forbes

http://www.w3.org/2001/XMLSchema#string

Yehuda Ringel

http://www.w3.org/2001/XMLSchema#string

P304

22-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

139786

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1004409

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21208106

http://www.w3.org/2001/XMLSchema#string

P921